Buradasınız

Anasayfa » Content

Erektil Disfonksiyonlu Hastalarda Sildenafil Sitratın Klinik Etkinliği ve Güvenilirliği

Efficacy And Safety Of Sildenafil Citrate in Patients With Erectile Dysfunction

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
The objective of this study was to assess the efficacy and safety of sildenafil citrate in patients with erectile dysfunction. From August 1999 to July 2002, 101 patients were given sildenafil citrate for erectile dysfunction. The mean age and duration of erectile dysfunction were 52 ± 3.7 years; age range 35-74 years and 28 ± 16 months, respectively. The severity of erectile dysfunction and clinical outcome were assessed subjectively by international index of erectile function and global efficacy questions. The patients followed-up for 3 months. Satisfactory erections assessed by global efficacy questions and international index of erectile function occurred in 79.2% of patients. Side effects in the form of headache, flushing, nasal congestion and blurred vision were recorded in 19 patients (18.8%). With respect to comorbid profiles, regardless of severity of erectile dysfunction, an efficacy of 83.3% was recorded in ischemic heart disease patients. Oral sildenafil citrate has been shown to be an effective and safe drug in men with erectile dysfunction
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmanın amacı, erektil disfonksiyon yakınması olan hastalarda sildenafil sitratın etkinliğinin ve güvenilirliğinin belirlenmesidir. Ağustos 1999 ve Temmuz 2002 tarihleri arasında erektil disfonksiyon yakınması olan 101 hastaya oral sildenafil sitrat verildi. Hastaların ortalama yaşı 52 ± 3.7 (35-74 yaş arası) ve erektil disfonksiyon yakınmasının ortaya çıkış süresi ortalama 28 ± 16 ay olarak belirlendi. Erektil disfonksiyonun şiddeti ve tedaviye alınan klinik yanıt uluslararası erektil fonksiyon endeksi ve global etkinlik sorgulaması ile subjektif olarak değerlendirildi. Hastalar 3 ay süre ile takip edildi. Hastaların %79.2’sinde uluslararası erektil fonksiyon endeksi ve global etkinlik sorgulaması ile değerlendirilen tatminkar ereksiyonlar meydana geldi. 19 hastada (%18.8), başağrısı, ateş basması, nasal konjesyon ve görme bulanıklığı gibi yan etkiler gelişti. Eşlik eden kronik hastalıklarına göre olgular ED şiddetine bakılmaksızın ilaca verdikleri olumlu yanıta göre değerlendirildiğinde en iyi yanıt (%83.3) iskemik kalp hastalığı olan grupta alındı. Oral sildenafil sitratın erektil disfonksiyonu olan hastalarda etkili ve güvenilir bir ilaç olduğu görülmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-erektil-disfonksiyonlu-hastalarda-sildenafil-sitratin-klinik-etkinligi-guvenilirligi.pdf
  • 1
15-18
  • Turkish

REFERENCES

References: 

1. NIH Consensus Development Panel on Impotance.
Impotence. JAMA 1995; 270: 83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence
and its medical and psychosocial correlates: results of the
Massachusetts Male Aging Study. J Urol 1994; 151:54-61.
3. Kaiser FE. Erectile dysfunction in the aging man. In: Kaiser
FE (eds.). The Medical Clinics of North America: The aging
Male Patient. Philadelphia: WB Saunders Co.; 1999;83:
1267-78. İ. Yavaşçaoğlu, ark.
18
4. Carson CC, Burnett AL, Levine AL, Nehra A. The efficacy
of sildenafil citrate in clinical populations: an update.
Urology 2002; 60 (Suppl 2): 12-27.
5. Lim PHC, Li MK, Cheong F, et al. Clinical efficacy and
safety of sildenafil citrate in a multi-racial population in
Singapore: A retrospective study of 1520 patients. Int J Urol
2002; 9: 308-315.
6. Data on file. Pfizer Inc., New York, February 2002.
7. Meuleman E, Cuzin B, Opsomer RJ, et al. A dose escalation
study to ases the efficacy and safety of sildenafil citrate in
men with erectile dysfunction. Br. J Urol 2001; 87: 75-81.
8. Mc Mahon CG, Samali R, Johnson H. Efficacy, safety and
patient acceptance of sildenafil citrate as treatment for
erectile dysfunction. J Urol 2000; 164: 1192-6.
9. Moreira SG, Branningan RE, Spitz A, et al. Side-effect
profile of sildenafil of sildenafil citrate (Viagra) in clinical
practice. Urology 2000; 56: 474-6.
10. Rosen RC, Riley A, Wzgner G et al. The International Indeks
of Erectil Function (IIEF): A multidimensinal scale for
assesment of erectile dysfunction. Urology 1997; 49: 822-
830.
11. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in
the treatment of erectile dysfunction. N Engl J Med 1998;
338:1397-404.
12. Padma-Nathan H, Steers WD, Wicker PA, et al. Efficacy and
safety oferectile dysfunction: A double-blind, placebo
controlled study of 329 patients. Sildenafil Study Group Int J
Clin Pract 1998; 52:375-9.
13. Christiansen E, Guirguis WR, Osterloh IH. Long-term
efficacy and safety or oral Viagra (sildenafil citrate) in men
with erectile dysfunction and the effect of randomised
treatment withdrawal. Sildenafil Multicentre Study group. Int
J Impot Res 2000; 12: 177-82.
14. Magoha GA. Sildenafil (Viagra) in the treatment of male
erectile dysfunction in Nairobi. East Afr Med J 77:76-79,
2000.
15. Tarhan F, Baykal H, Eryıldırım B ve ark. Sildenafil sitrat
erektil disfonksiyonlu hastalarda etiyolojik ayırımda kullanı-
labilir mi? Türk Üroloji Dergisi 2001; 27 (3):311-15.
16. Young JM, Bennett C, Gilhooly P,et al. Efficacy and safety
of sildenafil citrate (Vigra) in black and hispanic american
men. Urology 2002; 60 (Suppl 2B):39-48.
17. Buffum J. Prescription drugs and sexuel function. Psychol.
Med 1992; 10:181-98.
18. Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for
treatment of erectile dysfunction in men with diabetes:A
randomised controlled trial. JAMA 1999; 281:421-65.

Thank you for copying data from http://www.arastirmax.com